- HOME
- Vol.47 No.11
- CLINICA NEUROL, 47: 877|879, 2007
- Vol.47 No.11 contents
The 48th Annual Meeting of the Japanese Society of Neurology
Treatment of seronegative myasthenia garvis
Masakatsu Motomura, M.D.
First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University
Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction. It is classified into 1) the nicotinic acetylcholine receptor antibodies (80-85%), 2) muscle- specific tyrosine kinase antibodies (5-10%), and 3) the above-mentioned antibody absent, double seronegative MG. In this symposium, I focused the treatment of double seronegative MG.
(CLINICA NEUROL, 47: 877|879, 2007)
key words: myasthenia gravis, acetylcholine receptor, muscle- specific tyrosine kinase, autoantibody
(Received: 16-May-07)